Novel Cell-Type Therapeutic Platforms in Oncology (Part II): A Cell by Any Other Name...Does Not Work the Same

Date: Tuesday, January 26, 2021
Time: 12:00 PM - 1:15 PM EST
9:00 AM - 10:15 AM PST
5:00 PM - 6:15 PM GMT
6:00 PM - 7:15 PM CET

Joel S. Sandler, PhD Principal
Cello Health BioConsulting
Debora Barton, MD
Carisma Therapeutics
Charles Nicolette, PhD
CoImmune Inc.
Kimberly Noonan, PhD, MPH
EVP, CSO and Founder
WindMIL Therapeutics

Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry, investor, and oncologist communities alike. A fundamental but often vaguely understood component of emerging cell therapy platforms is the cell itself. In addition to peripherally-derived T-cells found in branded CAR-T products (Novartis’s Kymriah and Gilead’s Yescarta), additional cell-types are being developed as the foundation of different cell-type platforms.

But why should investors and Pharma partners deploy scarce resources to develop novel cell-types? Can they unlock value and address shortcomings of first-mover CAR-T brands? Can they be delivered as truly ‘off-the-shelf’ products? Can they reproducibly address solid tumors?

In this, the second installment in the Novel Cell-Types whitepaper and webinar series, we will explore the role of engineered macrophages (CAR-Ms), cytokine-induced killer cells (CAR-CIKs), and marrow-infiltrating lymphocytes (MILs, CAR-MILs), and the respective companies pioneering each of them. Please join us for what promises to be a provocative discussion as we attempt to answer some of these questions and explore the overlay between the science, value proposition, and strategic positioning of emerging novel cell-type platforms.

We also invite you to download our related white paper: Proliferation of Novel Cell-Type Platforms in the Oncology Competitive Landscape PART II (Part I is available here), in which we profile Kiadis Pharma, Incysus Therapeutics and Kuur Therapeutics in terms of their positioning within the cell therapy landscape based on our recent discussions with their executive management along with our own knowledgebase and in-house cell therapy databases that we curate for clients at Cello Health BioConsulting.

Cello Health BioConsulting is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent, objective and actionable strategic advice to realize value across all therapeutic areas and stages of development. To learn more about us, please visit our website at

Keep In Touch


SAVE THE DATE – CANCER PROGRESS (VIRTUAL) 2021 | @CPbyCelloHealth | #CancerProgressNYC21


Cello Health BioConsulting
Previously Defined Health
25-B Hanover Road, Suite 320
Florham Park, NJ 07932 | |